Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805112 | 0.89 | RAB9A (0.58) | F10KCNH2F2DEGS1RAB9A | |
| SCHEMBL890791 | 0.89 | F10 (0.57) | F10KCNH2F2DEGS1RAB9A | |
| SCHEMBL254113 | 0.89 | F10 (0.72) | F10KCNH2F2 | |
| SCHEMBL14366426 | 0.89 | F10 (0.58) | F10KCNH2F2DEGS1RAB9A | |
| SCHEMBL14366428 | 0.88 | F10 (0.56) | F10KCNH2F2DEGS1RAB9A | |
| Hydrochloric Acid SCHEMBL160886 | 0.88 | F10 (0.71) | F10KCNH2F2 | |
| SCHEMBL10179154 | 0.87 | F10 (0.50) | F10KCNH2F2DEGS1RAB9A | |
| SCHEMBL14404554 | 0.86 | F10 (0.54) | F10KCNH2F2DEGS1RAB9A | |
| SCHEMBL14448366 | 0.86 | F10 (0.54) | F10KCNH2F2DEGS1RAB9A | |
| SCHEMBL13348892 | 0.84 | F10 (0.80) | F10KCNH2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885KCNH2 1032/4885F2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.